期刊文献+

肠道病毒71型VP3结构蛋白的原核表达 被引量:3

Optimization of prokaryotic expression of enterovirus 71 VP3 capsid protein
下载PDF
导出
摘要 目的利用大肠杆菌原核表达系统优化表达纯化肠道病毒71型(EV71)VP3结构蛋白,为后续单克隆抗体制备及检测试剂盒研发提供前期基础。方法采用PCR方法扩增EV71病毒VP3基因,将其插入表达载体pET28a(+),构建pET28a-VP3重组质粒,转化大肠杆菌BL21(DE3)菌株,分别在25℃、37℃下经IPTG诱导表达,重组表达的蛋白产物经凝胶电泳初步分析,比较不同温度诱导表达的蛋白产物。结果成功构建pET28a-VP3重组质粒,不同温度下诱导表达的蛋白产物在30.5 k Da左右位置均出现目的条带;37℃下诱导表达的蛋白超声破碎并离心后,目的蛋白基本位于沉淀中,而25℃诱导表达的蛋白产物有少量目的蛋白溶解于上清液中。结论在25℃或37℃下均能利用大肠杆菌原核表达系统有效表达EV71病毒VP3蛋白;37℃诱导时蛋白可融性表达低,目的蛋白获取效率较高。 Objective To express VP3 capsid protein of enterovirus 71 by using Escherichia coli prokaryotic expression system. Methods VP3 gene was amplified by PCR before inserted into p ET28a(+) plasmid. Then the plasmid p ET28a-VP3 was transformed and expressed in the Escherichia coli BL21 strain at 25 ℃ or 37 ℃. Finally the protein was analyzed by SDS-PAGE gel electrophoresis. Results The p ET28a-VP3 plasmid was successfully constructed,and the EV71VP3 protein was expressed. Supernatant of the production after ultrasonication and centrifugation got a little VP3 protein.Conclusion The EV71 VP3 protein was expressed. Expression at 25 ℃ may lead to the dissolution of the recombinant protein.
出处 《广州医药》 2017年第4期38-41,共4页 Guangzhou Medical Journal
关键词 肠道病毒71型 VP3蛋白 原核表达 pET28a Enterovirus 71 VP3 protein Prokaryotic expression pET28a
  • 相关文献

参考文献3

二级参考文献34

  • 1许文波.手足口病的流行病学特征及控制策略[J].中华实验和临床病毒学杂志,2007,21(2). 被引量:72
  • 2中华人民共和国卫生部.卫生部公布2010年1月及2009年度全国法定传染病疫情[EB/OL].[2010-01-25].http://www.moh.gov.cn/publicfiles//business/htmlfiles/wsb/pyqxx/list.htm.
  • 3中国疾病预防控制中心.手足口病预防控制指南(2009版)[EB/OL].(2009-06-12).www.chinacdc.en/11272442/n272530/n3479265/n3479308/31860.htmt.
  • 4Chen KT,Chang HL,Wang ST,et al.Epidemiologic features ofhand-foot-mouth disease and herpangina caused by enterovirus 71in Taiwan,1998-2005[J].Pediatrics,2007,120(2):e244-e252.
  • 5Veldkamp KE, Heezius HC, Verhoef J, et al. Modula- tion of neutrophil chemokine receptors by staphylococcus aureus supemate [J] . Infection and Immunity, 2000, 68 (10): 5908-5913.
  • 6Russell R J, Wilkinson PC, Mclnroy R J, et al. Effects of staphylococcal products on locomotion and chemotaxis of human blood neutrophils and monocytes [ J ] . J Med Mi- crobiol, 1976, 9 (4): 433-439.
  • 7Karin Ellen de Hass, Carla JC. Veldkamp, et al. chemo- taxis inhibitory protein of staphylococcus aureus, C, A bacterial antiinflammatory Agent [J] . J Exp Med, 2004, 199 (5): 687-695.
  • 8Hass PJ, de Hass C J, Kleibeuker W, et al. N-terminal residues of the chemotaxis inhibitory protein of Staphylo-coccus aureus are essential for blocking formylated pep- tide receptor but not C5a receptor [J] . J Immunol, 2004, 173 (9): 5704-5711.
  • 9J.萨姆布鲁克,D.W.拉塞尔.分子克隆实验指南[M].3版.北京:科学出版社,2008.
  • 10Wenzel-Seifert K, Grunbaum L, Seifert R. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H: cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation [J] .Jlmmunol, 1991, 147 (6): 1940-1946.

共引文献69

同被引文献32

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部